1/15
11:52 am
kymr
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]
Medium
Report
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]
1/15
08:02 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
1/13
07:00 am
kymr
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Low
Report
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
1/12
01:51 pm
kymr
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]
1/7
01:33 pm
kymr
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]
Low
Report
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]
1/6
07:00 am
kymr
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Low
Report
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
12/22
09:02 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
12/16
08:43 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/15
01:12 pm
kymr
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]
Low
Report
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]
12/11
04:01 pm
kymr
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/11
09:57 am
kymr
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
Low
Report
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
12/11
08:06 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
12/11
08:05 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
12/11
07:31 am
kymr
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]
12/11
07:00 am
kymr
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
Low
Report
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
12/10
11:04 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $125.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $125.00. They now have an "overweight" rating on the stock.
12/10
12:10 am
kymr
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering [Yahoo! Finance]
12/9
11:30 pm
kymr
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
Low
Report
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
12/9
03:05 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/9
10:04 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $116.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $116.00 price target on by analysts at Truist Financial Corporation.
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/9
08:46 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/9
08:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.